Advertisement

Drugs

, Volume 79, Issue 13, pp 1455–1466 | Cite as

Glycopyrronium/Formoterol: A Review in COPD

  • Zaina T. Al-SalamaEmail author
  • James E. Frampton
Adis Drug Evaluation
  • 133 Downloads

Abstract

Glycopyrronium/formoterol (Bevespi Aerosphere®) is a fixed-dose combination of the long-acting muscarinic antagonist glycopyrronium bromide and the long-acting β2-agonist formoterol fumarate delivered via a pressurized metered dose inhaler (pMDI) and formulated using co-suspension delivery technology. It is approved in the USA and EU for use as maintenance treatment in patients with chronic obstructive pulmonary disease (COPD) and in Japan to relieve symptoms in patients with COPD. In the PINNACLE trials in patients with moderate to very severe COPD, glycopyrronium/formoterol was associated with significantly greater improvements in lung function than its monocomponents and placebo at 24 weeks and its monocomponents and open-label tiotropium over 52 weeks. In the AERISTO trial, glycopyrronium/formoterol was non-inferior to umeclidinium/vilanterol dry powder inhaler for peak change in forced expiratory volume in 1 s (FEV1) within 2 h postdose, but not for the change in morning predose trough FEV1, over 24 weeks. Glycopyrronium/formoterol was generally well tolerated in patients with moderate to very severe COPD, with most adverse events (AEs) being of mild or moderate severity. Thus, glycopyrronium/formoterol pMDI formulated using co-suspension delivery technology is a useful new addition that extends treatment options for patients with COPD.

Notes

Acknowledgements

During the peer review process, the manufacturer of glycopyrronium/formoterol was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Zaina T. Al-Salama and James E. Frampton are salaried employees of Adis International Ltd/Springer Nature, are responsible for the article content and declare no relevant conflicts of interest.

References

  1. 1.
    Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. http://www.goldcopd.org/. Accessed 08 Aug 2019.
  2. 2.
    AstraZeneca Pharmaceuticals. Bevespi Aerosphere™ (glycopyrrolate and formoterol fumarate) inhalation aerosol: US prescribing information. 2016. http://www.azpicentral.com/. Accessed 08 Aug 2019.
  3. 3.
    European Medicines Agency. Summary of product characteristics: Bevespi Aerosphere 7.2 micrograms/5 micrograms pressurised inhalation, suspension. 2019. http://www.ema.europa.eu/. Accessed 08 Aug 2019.
  4. 4.
    AstraZeneca Pharmaceuticals. Bevespi Aerosphere (glycopyrronium/formoterol fumarate): Japanese prescribing information. 2019. http://www.pmda.go.jp/. Accessed 08 Aug 2019.
  5. 5.
    Martinez FJ, Rabe KF, Ferguson GT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–57.CrossRefGoogle Scholar
  6. 6.
    Vehring R, Lechuga-Ballesteros D, Joshi V, et al. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28(42):15015–23.CrossRefGoogle Scholar
  7. 7.
    Vos W, De Backer J, Schroeder J, et al. In-silico assessment of airway deposition using functional respiratory imaging for mono, dual and triple combination co-suspension metered dose inhaler formulations [abstract no. A5811 plus poster P1305]. Am J Respir Crit Care Med. 2016;193.Google Scholar
  8. 8.
    Doty A, Schroeder J, Vang K, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech. 2018;19(2):837–44.CrossRefGoogle Scholar
  9. 9.
    Taylor G, Warren S, Dwivedi S, et al. Gamma scintigraphic pulmonary deposition study of glycopyrronium/formoterol metered dose inhaler formulated using co-suspension delivery technology. Eur J Pharm Sci. 2018;111:450–7.CrossRefGoogle Scholar
  10. 10.
    Pudi K, Feldman G, Fakih F, et al. An open-label study evaluating the performance of the dose indicator in a metered dose inhaler delivering glycopyrrolate and formoterol fumarate in patients with moderate-to-very severe chronic obstructive pulmonary disease. J Aerosol Med Pulm Drug Deliv. 2019;1(23):40–6.CrossRefGoogle Scholar
  11. 11.
    Fakih F, Spangenthal S, Sigal B, et al. Randomized study of the effects of Aerochamber Plus(R) Flow-Vu(R) on the efficacy, pharmacokinetics and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler in patients with chronic obstructive pulmonary disease. Respir Med. 2018;138:74–80.CrossRefGoogle Scholar
  12. 12.
    Carter NJ. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease. Drugs. 2013;73(7):741–53.CrossRefGoogle Scholar
  13. 13.
    Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs. 2004;64(14):1597–618.CrossRefGoogle Scholar
  14. 14.
    McCormack PL, Lyseng-Williamson KA. Budesonide/formoterol: a review of its use as maintenance and reliever inhalation therapy in asthma. Drugs. 2007;67(16):2407–31.CrossRefGoogle Scholar
  15. 15.
    Scott LJ. Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease. Drugs. 2012;72(3):395–414.CrossRefGoogle Scholar
  16. 16.
    De Backer W, De Backer J, Vos W, et al. A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD. Int J Chron Obstruct Pulm Dis. 2018;13:2673–84.CrossRefGoogle Scholar
  17. 17.
    De Backer W, De Backer J, Vos W, et al. Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in COPD [abstract no. A3277 plus poster 465]. Am J Respir Crit Care Med. 2019;199.Google Scholar
  18. 18.
    Ferguson GT, Reisner C, Pearle J, et al. Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. Pulm Pharmacol Ther. 2018;49:67–74.CrossRefGoogle Scholar
  19. 19.
    Fabbri L, Rodriguez-Roisin R, Orevillo C, et al. Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators [abstract no. 3950]. Eur Respir J. 2013;42(Suppl 57).Google Scholar
  20. 20.
    Ferguson GT, Rodriguez-Roisin R, Reisner C, et al. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD. Int J Chron Obstruct Pulm Dis. 2018;13:945–53.CrossRefGoogle Scholar
  21. 21.
    European Medicines Agency. Bevespi Aerosphere (glycopyrronium bromide/formoterol): EU assessment report. 2018. http://www.ema.europa.eu/. Accessed 08 Aug 2019.
  22. 22.
    Reisner C, Miller J, DePetrillo P, et al. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects. Pulm Pharmacol Ther. 2018;53:33–8.CrossRefGoogle Scholar
  23. 23.
    Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–78.CrossRefGoogle Scholar
  24. 24.
    Reisner C, Gottschlich G, Fakih F, et al. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respir Res. 2017;18(1):157.CrossRefGoogle Scholar
  25. 25.
    Lipworth BJ, Collier DJ, Gon Y, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulm Dis. 2018;13:2969–84.CrossRefGoogle Scholar
  26. 26.
    Maltais F, Ferguson GT, Feldman GJ, et al. A randomized, double-blind, double-dummy study of glycopyrrolate/formoterol fumarate metered dose inhaler relative to umeclidinium/vilanterol dry powder inhaler in COPD. Adv Ther. 2019.  https://doi.org/10.1007/s12325-019-01015-3.Google Scholar
  27. 27.
    Hanania NA, Tashkin DP, Kerwin EM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel co-suspension delivery technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–15.CrossRefGoogle Scholar
  28. 28.
    Tashkin DP, Martinez FJ, Rodriguez-Roisin R, et al. A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe COPD. Respir Med. 2016;120:16–24.CrossRefGoogle Scholar
  29. 29.
    Reisner C, Orevillo C, Fernandez C, et al. Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 mg for phase III development [abstract no. 5185]. Eur Respir J. 2013;42(Suppl 57).Google Scholar
  30. 30.
    Sethi S, Fogarty C, Hanania NA, et al. Efficacy of formoterol fumarate delivered by metered dose inhaler using co-suspension delivery technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a randomized, dose-ranging study. Chronic Obstr Pulm Dis. 2016;4(1):21–33.Google Scholar
  31. 31.
    Fabbri LM, Kerwin EM, Spangenthal S, et al. Dose-response to inhaled glycopyrrolate delivered with a novel co-suspension delivery technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD. Respir Res. 2016;17(1):109.CrossRefGoogle Scholar
  32. 32.
    Reisner C, Fernandez C, St Rose E, et al. Characterization of the dose response of Pearl Therapeutics’ LAMA MDI (GP MDI, PT001) from 36 micrograms to 600 nanograms BID; results from an integrated analysis of phase IIb studies in patients with COPD [abstract no. A4274]. Am J Respir Crit Care Med. 2013;187.Google Scholar
  33. 33.
    Kerwin EM, Spangenthal S, Kollar C, et al. A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD. Respir Res. 2018;19(1):38.CrossRefGoogle Scholar
  34. 34.
    AstraZeneca Pharmaceuticals. A randomized, double-blind, chronic dosing (24 weeks), placebo-controlled, parallel group, multi-center study to assess the efficacy and safety of PT003, PT005, and PT001 in subjects with moderate to very severe COPD, compared with placebo (revised clinical study protocol). 2017. http://clinicaltrials.gov/ProvidedDocs/58/NCT02343458/Prot_000.pdf. Accessed 08 Aug 2019.
  35. 35.
    Pearl Therapeutics Inc. Efficacy and safety of PT003, PT005 and PT001 in subjects with moderate to very severe chronic obstructive pulmonary disease (COPD); (PINNACLE 1) [clinical trial protocol: PT003006-02]. 2016. http://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=23713. Accessed 08 Aug 2019.
  36. 36.
    Pearl Therapeutics Inc. Multi-center study to assess the efficacy and safety of PT003, PT005 and PT001 in subjects with moderate to very severe COPD (PINNACLE 2) [clinical trial protocol: PT003007-02]. 2016. http://astrazenecagrouptrials.pharmacm.com/ST/Submission/View?id=23714. Accessed 08 Aug 2019.
  37. 37.
    Zhong N, Chen R, Wang HY, et al. Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Chinese patients with COPD [abstract no. AO199]. Respirology. 2018;23 (Suppl 2):81.Google Scholar
  38. 38.
    Gon Y, Nishi K, Sato K, et al. Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD [abstract no. PA1014]. Eur Respir J. 2018;52(Suppl 62).Google Scholar
  39. 39.
    Lipworth BJ, Collier DJ, Feldman GJ, et al. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in symptomatic patients with COPD: a post-hoc analysis from a phase III, randomized, placebo-controlled study (PINNACLE-4) [abstract no. A3342]. Am J Respir Crit Care Med. 2019;199.Google Scholar
  40. 40.
    Martinez FJ, Rabe KF, Rodriguez-Roisin R, et al. Pooled analyses from PINNACLE-1 and -2: the novel LAMA/LABA co-suspension technology glycopyrrolate/formoterol fixed-dose combination delivered by MDI shows improvement versus monocomponents in patients with COPD [abstract no. A6782]. Am J Respir Crit Care Med. 2016;193.Google Scholar
  41. 41.
    Martinez FJ, Rabe KF, Rodriguez-Roisin R, et al. Beneficial effect of the novel LAMA/LABA co-suspension technology of glycopyrrolate/formoterol fixed-dose combination delivered by MDI in GOLD A and B COPD patients: pooled analyses from PINNACLE-1 and -2 [abstract no. A6785]. Am J Respir Crit Care Med. 2016;193.Google Scholar
  42. 42.
    Fabbri LM, Martinez FJ, Rabe KF, et al. Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension™ delivery technology (GFF MDI), in COPD GOLD group A and B patients [poster PA310]. In: European Respiratory Society International Conference. 2016.Google Scholar
  43. 43.
    Martinez FM, Rabe KF, Lipworth BJ, et al. Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) improves lung function in GOLD category A patients with COPD: pooled data from the Phase III PINNACLE studies [abstract no. A3345 plus poster P534]. Am J Respir Crit Care Med. 2019;199.Google Scholar
  44. 44.
    Sethi S, Lipworth BJ, Ferguson GT, et al. Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in reducing exacerbation risk in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies [abstract no. A1588 plus poster P152]. Am J Respir Crit Care Med. 2019;199.Google Scholar
  45. 45.
    Aziz MIA, Tan LE, Wu DB, et al. Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulm Dis. 2018;13:3203–31.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Springer NatureAucklandNew Zealand

Personalised recommendations